title: Effects of exercise on fatigue, sleep, and performance: a randomized trial.
abstract: OBJECTIVE
  To compare usual care with a home-based individualized exercise program (HBIEP) in patients receiving intensive treatment for multiple myeloma (MM)and epoetin alfa therapy.
  
  
  METHODS
  Randomized trial with repeated measures of two groups (one experimental and one control) and an approximate 15-week experimental period.
  
  
  METHODS
  Outpatient setting of the Myeloma Institute for Research and Therapy at the Rockfellow Cancer Center at the University of Arkansas for Medical Sciences.
  
  
  METHODS
  187 patients with newly diagnosed MM enrolled in a separate study evaluating effectiveness of the Total Therapy regimen, with or without thalidomide.
  
  
  METHODS
  Measurements included the Profile of Mood States fatigue scale, Functional Assessment of Cancer Therapy-Fatigue, ActiGraph® recordings, 6-Minute Walk Test, and hemoglobin levels at baseline and before and after stem cell collection. Descriptive statistics were used to compare demographics and treatment effects, and repeated measures analysis of variance was used to determine effects of HBIEP.
  
  
  METHODS
  Fatigue, nighttime sleep, performance (aerobic capacity) as dependent or outcome measures, and HBIEP combining strength building and aerobic exercise as the independent variable.
  
  
  RESULTS
  Both groups were equivalent for age, gender, race, receipt of thalidomide, hemoglobin levels, and type of treatment regimen for MM. No statistically significant differences existed among the experimental and control groups for fatigue, sleep, or performance (aerobic capacity). Statistically significant differences (p < 0.05) were found in each of the study outcomes for all patients as treatment progressed and patients experienced more fatigue and poorer nighttime sleep and performance (aerobic capacity).
  
  
  CONCLUSIONS
  The effect of exercise seemed to be minimal on decreasing fatigue, improving sleep, and improving performance (aerobic capacity).
  
  
  CONCLUSIONS
  Exercise is safe and has physiologic benefits for patients undergoing MM treatment; exercise combined with epoetin alfa helped alleviate anemia.
authors.affiliation: College of Nursing, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA. colemanann@uams.edu
authors.forename: Elizabeth Ann
authors.initials: EA
authors.lastname: Coleman
authors.forename: Julia A
authors.initials: JA
authors.lastname: Goodwin
authors.forename: Robert
authors.initials: R
authors.lastname: Kennedy
authors.forename: Sharon K
authors.initials: SK
authors.lastname: Coon
authors.forename: Kathy
authors.initials: K
authors.lastname: Richards
authors.forename: Carol
authors.initials: C
authors.lastname: Enderlin
authors.forename: Carol B
authors.initials: CB
authors.lastname: Stewart
authors.forename: Paula
authors.initials: P
authors.lastname: McNatt
authors.forename: Kim
authors.initials: K
authors.lastname: Lockhart
authors.forename: Elias J
authors.initials: EJ
authors.lastname: Anaissie
mesh_terms: D000328:Adult; D000339:Affect; D000368:Aged; D000740:Anemia / Q000188:drug therapy / Q000209:etiology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000627:therapeutic use; D015444:Exercise; D005221:Fatigue / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D005260:Female; D006699:Home Care Services; D006801:Humans; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D009043:Motor Activity; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy / Q000523:psychology / Q000601:surgery / Q000628:therapy*; D009133:Muscular Atrophy / Q000517:prevention & control; D036102:Peripheral Blood Stem Cell Transplantation; D017286:Polysomnography; D011994:Recombinant Proteins / Q000627:therapeutic use; D055070:Resistance Training; D020919:Sleep Disorders, Intrinsic / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D013792:Thalidomide / Q000008:administration & dosage; D016138:Walking
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin; D013792:Thalidomide; D000068817:Epoetin Alfa